Dr. Michael Callegari, MBA, MD

Dr. Callegari practices at University Suburban Endoscopy Center - HOPD in South Euclid, Ohio.

Dr. Callegari's NPI, 1124524079, was assigned on March 31, 2018. Dr. Callegari holds Massachusetts license 1016883.

Dr. Callegari's primary practice is University Suburban Endoscopy Center - HOPD, at 1611 S Green Rd, South Euclid, OH 44121.

Dr. Callegari's primary practice is University Suburban Endoscopy Center - HOPD in South Euclid, Ohio. Dr. Callegari is also affiliated with University Hospitals Cleveland Medical Center. The medical group on file is University Eyecare. Dmand AI also links Dr. Callegari to 3 more hospitals and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Callegari practices, 5 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Callegari's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Callegari is licensed in Massachusetts.

CMS data shows 37 Medicare services from Dr. Callegari across 2 procedure codes in 2024, all of them office visits, for 46 Medicare patients. Medicare paid $2,437 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 46 Medicare patients who saw Dr. Callegari in 2024. The largest group is 65 to 74, with 20 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.75, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Callegari's median patient age at 72, with 16% women.

In 2024, Dr. Callegari wrote 97 Medicare Part D claims for 55 patients. 93% of them were for generic drugs. CMS names the drug for 29 of them, across 2 drugs with 11 or more claims each, at $183 in total drug cost. In 2023, CMS named 61 claims across 4 drugs.

Dr. Callegari accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Callegari as offering telehealth. CMS counts 15 procedures of prostate resection by Dr. Callegari, more than 72% of the clinicians it reports for that procedure.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 23 papers to Dr. Callegari, published from 2019 to 2025. 2022 was the busiest year, with 6. The most frequent topics are Anti-Bacterial Agents, Postoperative Complications and Anti-Infective Agents. Dr. Callegari has published most often in Urology. Dr. Callegari's most frequent co-authors are Megan Prunty, MD, Nannan Thirumavalavan, MD and Aram Benjamin Loeb, MD.

CMS Open Payments shows 36 general payments to Dr. Callegari from 15 drug and device companies from 2018 to 2025. Grants make up the largest share, 94% of the total. Boston Scientific Corporation paid the most, $52,161.